2. Helps weight management by helping you feel full longer.
3. Can be an important part of your overall good health.
4. Can help promote intestinal health.
5. Can help maintain beneficial intestinal flora and regularity.
6. Can support colon health.
7. Promotes a healthy digestive system.
8. Provides pre-biotic nutrients that support growth of beneficial bacteria.
Clinical studies show that SUGARDOWN® reduces glucose and fructose absorption from meals and sweetened drinks and reduces the two-hour after-meal blood sugar and insulin elevation.
Studies have been conducted at Dartmouth-Hitchcock Medical Center in the U.S. Sydney University-Glycemic Index Research Service (SUGiRS) in Australia and Chinese University of Hong Kong (ongoing). Studies at University of Minnesota also clearly show evidence that SUGARDOWN® inhibits enzymes such as Amylase from breaking down complex carbohydrates into sugar during food digestion.
Sydney University - Glycemic Index Research Service (SUGiRS)
Study Title: Determination of the postprandial glucose and insulin responses of white rice alone and white rice consumed with sugardown™
Objectives Of The Study
• The primary objective of the study was to determine the postprandial glucose responses to the three test meals.
• The secondary objective of the study was to determine the postprandial insulin responses to the three test meals.
This study shows that the consumption of SUGARDOWN® tablets prior to a high carbohydrate food significantly reduce the postprandial glucose and insulin responses to that meal. The lower dose of SUGARDOWN®, 3 tablets containing 6 g Mannan Polysaccharide and 4.5 g Sorbitol, resulted in a 19% reduction in postprandial glucose and 16% decrease in postprandial insulin response compared to the white rice consumed alone. The higher 6 tablet dose of SUGARDOWN®, containing 12 g Manna Polysaccharide and 9 g Sorbitol, produced a 32% reduction in the 2-hr glucose response and a 24% reduction in the postprandial insulin response compared to the white rice control meal. No serious adverse effects were reported or observed during the study and none of the subjects reported taking any medication.
Study Title:Safety and efficacy of the non-systemic chewable complex carbohydrate dietary supplement PAZ320 (“Sugardown”)on postprandial glycemia when added to oral agents or insulin in patients with Type 2 diabetes mellitus
Our primary objective was to evaluate the effect of the dietary supplement PAZ-320 on postprandial glucose excursion. PAZ-320 acts by blocking carbohydrate hydrolyzing enzymes and by binding to ingested polysaccharides. Endpoints included area under the curve during postprandial glucose excursion (gAUC) and adverse reactions.
PAZ-320 may be useful as an adjunct to decrease postprandial glycemia in type 2 diabetes, although patients should verify its effect on postprandial glucose due to a possible paradoxical response. Its safety profile is reassuring. Further study is required to determine its long-term effects on HbA1c and to further define which subpopulation may respond to PAZ-320.
Study Title: Determination of the glycemic and insulinemic index values of soft drink and two test meals containing soft drink consumed with sugardown™ in 10 healthy, overweight adults.
1. To determine the glycemic index (GI) values of the three meals containing soft drink consumed alone or with SugarDown™ tablets.
2. To determine the insulinemic index (II) values of the three meals containing soft drink consumed alone or with SugarDown™ tablets.
This study showed that the consumption of SugarDown™ tablets, containing mannan polysaccharide and sorbitol, prior to a sugary beverage significantly reduced the postprandial glucose and insulin responses to the that beverage. The addition of 2 SugarDown™ tablets, providing 2.6 g mannan polysaccharide and 4.6 g sorbitol, produced a 10% reduction in GI and a 14% decrease in II of the Sprite™ soft drink. The addition of 4 SugarDown™ tablets, providing 5.2 g mannan polysaccharide and 9.2 g sorbitol, produced a 14% and 18% reduction in GI and II, respectively, of the Sprite™ soft drink. A dose response effect was observed, such that the higher dose of SugarDown™ produced greater reductions in postprandial responses to the soft drink.
*The statements and products shown on this website have not been evaluated by the US Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Those seeking treatment for a specific disease should consult a qualified physician. All supplements should be taken as part of a healthy lifestyle. SugarDown® is a registered trademark of Boston Therapeutics.